Cited by 66Endometriosis Research and TreatmentEctopic Pregnancy Diagnosis and ManagementGynecological conditions and treatments

Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis

Open access
Wessels, Jocelyn M., Kay, Vanessa R., Leyland, Nicholas A., Agarwal, Sanjay K., Foster, Warren G.·2016·Fertility and Sterility

Abstract

OBJECTIVE: To evaluate novel clinical markers of endometriosis including the neurotrophins brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin 4/5 (NT4/5) and compare them to others previously reported in the literature including cancer antigen 125 (CA-125) and C-reactive protein (CRP). DESIGN: Prospective study. SETTING: University hospital. PATIENT(S): One hundred thirty-eight women were prospectively and consecutively recruited (April 2011-April 2015; cases: undergoing endometriosis surgery, n = 96; controls: benign gynecological surgery, n = 24 combined with healthy women, no history of pelvic pain, not undergoing surgery, n = 18). INTERVENTION(S): Collection of peripheral blood, gynecological and demographic information, eutopic biopsy in women undergoing laparoscopy. MAIN OUTCOME MEASURE(S): Circulating BDNF, NGF, NT4/5, CA-125, and CRP were quantified by ELISA. RESULT(S): Plasma concentrations of BDNF were significantly greater in women with endometriosis (1,091.9 pg/mL [640.4-1,683.1]; n = 68, untreated) than in controls (731.4 pg/mL [352.1-1,176.2]; n = 36), whereas circulating NGF, NT4/5, CA-125, and CRP were not different. When assessed for their ability to differentiate between women with revised Classification of the American Society of Reproductive Medicine stage 1 and 2 or stage 3 and 4 disease and controls, BDNF was the only putative marker able to identify stage 1 and 2 disease, with a sensitivity and specificity of 91.7% and 69.4%, respectively, using an arbitrary cutoff value of 1,000 pg/mL. We also demonstrated that circulating BDNF in women with endometriosis who were receiving ovarian suppression for disease was equivalent to that in the control group. This suggests that BDNF may also offer the opportunity to monitor patient response to treatment. CONCLUSION(S): Plasma BDNF is a potentially useful clinical marker of endometriosis that is superior to NGF, NT4/5, CA-125, and CRP.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2015.09.003

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Brain-derived neurotrophic factor (BDNF) is elevated in women with endometriosis compared to the control group.

    “Pain is a typical symptom of endometriosis, so the conduction pathways were analyzed and the brain-derived neurotrophic factor (BDNF) was found to be elevated in women with endometriosis compared to the control group [147].”
  • Plasma brain-derived neurotropic factor has been demonstrated as a noninvasive biomarker for detecting stage I-II endometriosis with 91.7% sensitivity and 69.4% specificity.

    “Furthermore, Wessels et al. demonstrated the effectiveness of plasma brain-derived neurotropic factor as a noninvasive biomarker for detecting patients with stage I-II endometriosis with 91.7% sensitivity and 69.4% specificity (78).”

    From Biomarkers in endometriosis: Challenges and opportunities (2017) · cites this paper as [78]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Borghese B, Vaiman D, Mondon F, Mbaye M, Anaf V, Noel JC, et al. Neurotrophins and pain in endometriosis. Gynecol Obstet Fertil 2010; 38:442-6.

Cited by

Sorted by citations

Authors
Wessels, J. M., Kay, V. R., Leyland, N. A., Agarwal, S. K., & Foster, W. G.
Affiliations
  • McMaster University (CA)
  • University of California San Diego (US)
Corresponding author
Foster, Warren G.
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2016-01
Volume
105
Issue
1
Pages
119-128.e5
ISSN
0015-0282 (ISSN-L)
OpenAlex
W2159823634
Cited by
66
References
27
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 11 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 5
FWCI
8.76
Type
journal article
Language
en
Open access
Locations
  • Fertility and Sterility (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research (MOP142230)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
Keywords
endometriosis, brain-derived neurotrophic factor, nerve growth factor, neurotrophin-4/5, CA125, C-reactive protein, plasma biomarkers, endometriosis staging, ovarian suppression, treatment response monitoring, neurotrophins, eutopic endometrium, pelvic pain, endometriosis surgery, sensitivity and specificity
MeSH terms
Adult, Endometriosis, Enzyme-Linked Immunosorbent Assay, Female, Humans, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Biomarkers, Up-Regulation, Case-Control Studies, Brain-Derived Neurotrophic Factor, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review